ClinicalTrials.gg
Status unknownNCT01898897ROBOTNGALUpdated Jul 16, 2013

Influence of Anesthesia Technique on Postoperative Evolution After Urogenital Surgical Interventions

An interventional study of epidural catheter insertion and robot assisted laparoscopic urogenital surgery in Anesthesia; Reaction, Adverse Effect of Other General Anesthetics and Adverse Anesthesia Outcome, sponsored by Iuliu Hatieganu University of Medicine and Pharmacy. Status unknown at 1 site in Romania. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-07-16.

Sponsored by Iuliu Hatieganu University of Medicine and Pharmacy · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jul 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study hypothesis is that regional anesthesia offers better outcome for the patients who underwent robot assisted laparoscopic urogenital surgery.

Read the detailed description

The study investigates the effect of combined anesthesia on occurrence of acute kidney injury in robot assisted laparoscopic urogenital surgery.Renal function is assessed according to the new RIFLE and AKIN criteria, and by determining serum and urinary neutrophil gelatinase associated lipocalin.

02

Conditions studied

  • Anesthesia; Reaction
  • Adverse Effect of Other General Anesthetics
  • Adverse Anesthesia Outcome
  • Acute Kidney Injury

Browse trials for

03

In context

Acute Kidney Injury

1,641 studies on the registry are indexed under Acute Kidney Injury; 380 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 786 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Iuliu Hatieganu University of Medicine and Pharmacy is the lead sponsor of 55 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed the informed consent without previous renal function alteration respiratory and hemodynamic stability

Exclusion criteria

Exclusion Criteria:

  • refuse to sign the informed consent chronic or and stage renal disease severe systemic diseases
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    robot general anesthesia

    General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed. Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools.

    Procedure: robot assisted laparoscopic urogenital surgery

  • Experimental
    robot combined anesthesia

    Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.

    Procedure: epidural catheter insertion · Procedure: robot assisted laparoscopic urogenital surgery

Interventions

  • Procedureepidural catheter insertion

    A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.

    Also known as: peridural anesthesia and analgesia

  • Procedurerobot assisted laparoscopic urogenital surgery

    The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.

06

What researchers measure

Primary outcomes

  1. acute kidney injury

    Acute kidney injury, previously referred as acute renal failure is a serious complication of major surgery. The diagnostic of subclinical alteration of kidney function is possible with the novel biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). Modified NGAL values can be detected in patients urine and serum at 6 hours from the renal injury. In our study, we assessed the renal function by determining basal creatinine and follow the creatinine values 4 days postoperative. Acute kidney injury (AKI)is defined as a 0.3 mg/ml rise in serum creatinine from baseline, according to the AKIN criteria. NGAL is measured (with ELISA technique) at 6 hours and 12 hours from the induction of the anesthesia. The incidence of AKI will be compared in the different anesthesia techniques for robot assisted urogenital laparoscopic surgery.

    Time frame: 4 days

Secondary outcomes

  1. postoperative outcome

    We study the effect of combined anesthesia (general anesthesia with epidural anesthesia and postoperative analgesia for 12 hours)on the postoperative outcome of patients who underwent robot assisted laparoscopic surgery. The endpoints that are discussed are perioperative morbidity, postoperative rehabilitation and the modification of host immune response to surgery. Postoperative rehabilitation is assessed by quality of recovery score (QoR-40). The modification of immune response is assessed by determining IL6, IL10 and TNFalfa levels. Post-prostatectomy increase in PSA (prostate specific antigen)indicates biochemic cancer recurrence.

    Time frame: 10 days

07

Study locations

1 of 1 sites recruiting
  • City Clinical Hospital Cluj Urology and ICU Departments
    Cluj-Napoca, Cluj 400139, Romania
    Recruiting
08

References and documents

Publications

  • Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. J Anesth. 2008;22(3):263-77. doi: 10.1007/s00540-008-0626-2. Epub 2008 Aug 7. PubMed 18685933 ↗
  • Rigg JR, Jamrozik K, Myles PS, Silbert BS, Peyton PJ, Parsons RW, Collins KS; MASTER Anaethesia Trial Study Group. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet. 2002 Apr 13;359(9314):1276-82. doi: 10.1016/S0140-6736(02)08266-1. PubMed 11965272 ↗
  • Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5. doi: 10.1093/oxfordjournals.bja.a013366. PubMed 10740540 ↗
  • Curatolo M. Adding regional analgesia to general anaesthesia: increase of risk or improved outcome? Eur J Anaesthesiol. 2010 Jul;27(7):586-91. doi: 10.1097/EJA.0b013e32833963c8. PubMed 20404731 ↗
  • Wolf AR. Effects of regional analgesia on stress responses to pediatric surgery. Paediatr Anaesth. 2012 Jan;22(1):19-24. doi: 10.1111/j.1460-9592.2011.03714.x. Epub 2011 Oct 14. PubMed 21999144 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jan 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2013
First posted
Jul 15, 2013
Start
Mar 2010
Primary completionEst.
Jan 2015
CompletionEst.
May 2015
Last update
Jul 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01898897
Lead sponsor
Iuliu Hatieganu University of Medicine and Pharmacy
Responsible party
Mihaly Orsolya (MD, PhD, Iuliu Hatieganu University of Medicine and Pharmacy) — Principal investigator
First posted
Jul 15, 2013
Start date
Mar 2010
Primary completion
Jan 2015 (estimated)
Completion
May 2015 (estimated)
Last update
Jul 16, 2013

Study contacts

Orsolya Mihaly, MD, Phd
Contact
kerekesorsolya@yahoo.com
Sorana Bolboaca, MD, Phd
Contact
sbolboaca@gmail.com
Daniela Ionescu, MD, Phd
study director · Iuliu Hatieganu University of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion